HARVINDER SINGH MD NPI 1043267354

NPI Details

Harvinder Singh, MD is a hematology and oncology internal medicine in Baltimore, MD with 34 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Harvinder Singh, MD NPI is 1043267354. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

22 S GREENE ST
BALTIMORE, MD
ZIP 21201-544
Phone: (410) 553-8360
Fax: (410) 553-8359

The NPI 1043267354 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)

The enumeration date for this NPI number is 5/30/2006 and was last updated on 3/8/2011.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.